Synthesis and evaluation of olmesartan medoxomil complex with SBE7 β-cd for enhanced dissolution and bioavailabiliTY

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 8, Issue 1, 2016, Pages 333-343

  Gera, Sonia ^a   Cheruvu, Srikanth ^a   Zakkula, Ashok ^a   Sampathi, Sunitha ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Complexation; Molecular modelling; Olmesartan medoxomil; Relative bioavailability; Sulphobutyl ether7 cyclodextrin

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; OLMESARTAN;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; ENCAPSULATION; FREEZE DRYING; INFRARED SPECTROSCOPY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MOLECULAR DOCKING; MOLECULAR INTERACTION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STOICHIOMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; X RAY DIFFRACTION;

EID: 84952944989     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. L Bajerski, RC Rossi, CL Dias, AM Bergold, PE Fröehlich. Development and validation of a discriminating in vitro dissolution method for a poorly soluble drug, olmesartan medoxomil: comparison between commercial tablets. AAPS PharmSciTech 2010;11:637-44.
2. H Koike, T Konse, T Sada, T Ikeda, A Hyogo, D Hinman, et al. Olmesartan medoxomil, a potent novel angiotensin II blocker. Annu Rep Sankyo Res Lab 2003;55:1-91.
3. M Fukuda, DA Miller, NA Peppas, JW McGinity. Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion. Int J Pharm 2008;350:188-96.
4. GL Amidon, H Lennernäs, VP Shah, JR Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20.
5. O Sagirli, A Önal, S Toker, D Şensoy. Simultaneous HPLC analysis of olmesartan and hydrochlorothiazide in combined tablets and in vitro dissolution studies. Chromatographic 2007;66:213-8.
6. BS Lee, MJ Kang, WS Choi, YB Choi, HS Kim, SK Lee, et al. Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability. Arch Pharmacal Res 2009;32:1629-35.
7. B Chen, D Lu, Y Fu, J Zhang, X Huang, S Cao, D Xu, et al. Olmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and p53. Br J Pharmacol 2014;171:3741-53.
8. N Fukuda, N Kobayashi, A Nagase, R Suzuki, T Ueno. Olmesartan improves the formation of impaired epcs and renal degeneration through activation of the ACE2/Ang-(1-7)/Mas receptor axis in shs. J Hypertens 2014;3:1-6.
9. T Miyoshi, A Hirohata, S Usui, K Yamamoto, T Murakami, I Komatsubara, et al. Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial. Heart Vessels 2014;29:178-85.
10. ME Brewster, T Loftsson. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Delivery Rev 2007;59:645-66.
11. SF Lockwood, S O'Malley, GL Mosher. Improved aqueous solubility of crystalline astaxanthin (3, 3'-dihydroxy-beta, beta-carotene-4, 4'-dione) by Captisol (sulfobutyl ether beta-cyclodextrin). J Pharm Sci 2003;92:922-6.
12. Y Nagase, M Hirata, H Arima, S Tajiri, Y Nishimoto, F Hirayama, et al. Protective effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced hemolysis in vitro. J Pharm Sci 2002;91:2382-9.
13. AM Totterman, NG Schipper, DO Thompson, JP Mannermaa. Intestinal safety of water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: effects on human intestinal epithelial Caco-2 cells. J Pharm Pharmacol 1997;49:43-8.
14. AS Jain, AA Date, RR Pissurlenkar, EC Coutinho, MS Nagarsenker. Sulfobutyl ether7 β-Cyclodextrin (SBE7 β-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity. AAPS Pharm Sci Tech 2011;12:1163-75.
15. H Yano, P Kleinebudde. Improvement of dissolution behavior for the poorly water-soluble drug by application of cyclodextrin in extrusion process: comparison between melt extrusion and wet extrusion. AAPS PharmSciTech 2010;11:885-93.
16. C dos Santos, P Buera, MF Mazzobre. Procedia phase solubility studies of terpineol with β-cyclodextrins and stability of the freeze-dried inclusion complex. Food Sci 2011;1:355-62.
17. Y Dotsikas, YL Loukas. Inclusion complex study between 6-p-toluidinylnaphthalene-2-sulfonate and 2-hydroxypropyl-beta-cyclodextrin. J Biochem Biophys Methods 2002;52:121-34.
18. A Gil, A Chamayou, E Leverd, J Bougaret, M Baron, G Couarraze, et al. Evolution of the interaction of a new chemical entity, eflucimibe, with γ-cyclodextrin during the kneading process. Eur J Pharm Sci 2004;23:123-9.
19. Y Lu, T Zhang, J Tao, G Ji S Wang. Preparation, characterization, and pharmacokinetics of the inclusion complex of genipin-beta-cyclodextrin. Drug Dev Ind Pharm 2009;35:1452-9.
20. CA Ventura, I Giannone, D Paolino, V Pistarà, A Corsaro, G Puglisi, et al. Preparation of celecoxib-dimethyl-β-cyclodextrin inclusion complex: characterization and in vitro permeation study. Eur J Med Chem 2005;40:624-31.
21. A Bernini, O Spiga, A Ciutti, M Scarselli, G Bottoni, P Mascagni, et al. NMR studies of the inclusion complex between β-cyclodextrin and paroxetine. Eur J Pharm Sci 2004;22:445-50.
22. IMF Cavalcanti, EAM Mendonça, MCB Lira, SB Honrato, CA Camara, RVS Amorim, et al. The encapsulation of β-lapachone in 2-hydroxypropyl-β-cyclodextrin inclusion complex into liposomes: a physicochemical evaluation and molecular modeling approach. Eur J Pharm Sci 2011;44:332-40.
23. KA Khan, CT Rhodes. Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv 1972;47:594-607.
24. CH Srikanth, T Chaira, S Sampathi, SVB, RB Bambal. Correlation of in vitro and in vivo plasma protein binding using ultra centrifugation and UPLC-tandem mass spectrometry. Analyst 2013;138:6106-16.
25. S Rawat, SK Jain. Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes. Eur J Pharm Biopharm 2004;57:263-7.
26. LS Ribeiro, DC Ferreira, FJ Veiga. Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with beta-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur J Pharm Biopharm 2003;20:253-66.
27. A Figueiras, RA Carvalho, L Ribeiro, JJ Torres-Labandeira, FJ Veiga. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin. Eur J Pharm Biopharm 2007;67:531-9.
28. N Kobayashi, I Fujimori, M Watanabe, T Ikeda. Real-time monitoring of metabolic reactions by microdialysis in combination with tandem mass spectrometry: hydrolysis of CS-866 in vitro in human and rat plasma, livers, and small intestines. Anal Biochem 2000;287:272-8.
29. B Yang, J Lin, Y Chen, Y Liu. Artemether/hydroxypropyl-beta-cyclodextrin host-guest system: characterization, phase-solubility and inclusion mode. Bioorg Med Chem 2009;17:6311-7.
30. T Loftsson, D Heinsdóttir, M Masson. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 2005;302:18-28.
31. F Cao, J Guo, Q Ping. Carvedilol solubility enhancement by inclusion complexation and solid dispersion. Drug Dev Ind Pharm 2005;31:747-75.
32. J Liu, L Qiu, J Gao, Y Jin. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-β-cyclodextrin. Int J Pharm 2006;312:137-43.